Fusion Biopsy Market Size to Surpass USD 3.12 Bn by 2030

The global Fusion Biopsy market size is expected to surpass around US$ 3.12 billion by 2030 and is anticipated to grow at a CAGR of 13.6% during forecast period 2021 to 2030.

Growth Factors

Increasing prevalence of prostate cancer, growing awareness about the importance of regular clinical interventions, and developing reimbursement policies are factors likely to boost the demand for targeted MR/ultrasound biopsy systems over the forecast period. An increasing number of radiologists gaining expertise in interpreting prostate MRI coupled with the implementation of standard image grading systems such as PI-RADS and Gleason score has increased the utilization rate of targeted MR/Ultrasound fusion biopsy systems.

Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/38468

Report Highlights

The transrectal segment dominated the market for fusion biopsy and accounted for the largest revenue share of 96.7% in 2020 because it was considered as the gold standard in performing prostate biopsy worldwide in the past decades. Most of the commercially available fusion biopsy was limited to the transrectal approach, contributing to its largest market share.  

Transperineal fusion biopsy is an emerging trend and is expected to experience the fastest CAGR of 25.2% during the forecast period. Lower risk of infection and rectal bleeding in comparison to the traditional approach is expected to contribute towards the segment growth. 

The hospitals segment dominated the market for fusion biopsy and held the largest revenue share of 71.0% in 2020 owing to their high purchasing power. The average unit price of a fusion biopsy system is expensive, making it unaffordable for private diagnostic centers. 

The diagnostics centers segment is expected to grow at a significant rate in the market for fusion biopsy over the forecast period. Shorter wait times, cost efficiency, and a developing reimbursement paradigm are the factors expected to drive the growth of this segment.

The ambulatory care centers segment is expected to grow at the fastest rate of 22.6% during the forecast period. The rising prevalence of prostate cancer in rural areas having limited access to healthcare services is the factor expected to drive the growth of the segment.

North America dominated the market for fusion biopsy and accounted for the largest revenue share of 56.2% in 2020 and is expected to continue its dominance over the forecast period. The Asia Pacific is anticipated to register the fastest growth in the fusion biopsy market. The presence of key players, increase in the incidence of prostate cancer, and development of healthcare infrastructure are factors likely to propel market growth.

In Asia Pacific, the market for fusion biopsy is anticipated to witness a CAGR of 22.0% during the forecast period. The Asia Pacific exhibits a lucrative growth opportunity with the emerging economies at the forefront of development. The major factors driving the growth of the market include rising awareness of prostate cancer, increasing population base, and rising disposable income levels as well as high unmet needs of the patients in emerging countries such as India,

Key Players

• MedCom
• ESAOTE SPA
• KOELIS
• Focal Healthcare
• GeoScan Medical
• UC-Care Medical Systems Ltd. 

Market Segmentation

• Biopsy Route
  • Transrectal
  • Transperineal
• End-use
  • Hospitals
  • Diagnostic Centers
  • Ambulatory Care Centers
• Regional
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Click Here to View Full Report Table of Contents

Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38468

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333